Open Access

Role of NO and other vascular mediators in the etiopathogenesis of necrotizing enterocolitis

Jayasree Nair1,*,Satyan Lakshminrusimha2
Department of Pediatrics, Division of Neonatology, State University of New York at Buffalo, Buffalo, New York, USA
Department of Pediatrics, University of California at Davis, Sacramento, California, USA
DOI: 10.2741/S524 Volume 11 Issue 1, pp.9-28
Published: 01 March 2019
(This article belongs to the Special Issue Epidemiology and etio-pathogenesis of necrotizing enterocolitis)
*Corresponding Author(s):  
Jayasree Nair

The etio-pathogenesis of necrotizing enterocolitis (NEC) is complex and multifactorial. Decades of research have not identified a definite etiology. Prematurity, enteral feeding, intestinal hypoxia/ischemia, inflammation and an abnormal microbiome are potential risk factors for developing this multisystem illness. Lack of specific diagnostic and prognostic markers adds to the challenges faced in managing NEC. Vascular mediators such as Nitric oxide (NO), catecholamines and endothelin (ET) regulate neonatal intestinal vascular resistance and may influence the pathophysiology of NEC. Neonatal morbidities, medications, transfusions, an altered microbiome and breast milk feeds may influence the vasculature in various ways. Better understanding of these mediators and their role in regulation of intestinal microcirculation and pathogenesis of NEC will assist in identifying strategies in prevention and management of this devastating illness.

Key words

Necrotizing Enterocolitis, Nitric Oxide, Endothelin, Vasoconstriction, Mesenteric Circulation, Neonatal, Review

2. Introduction

The neonatal intestinal vasculature undergoes significant changes after birth as it transitions into an organ of nutrient absorption. It is regulated by a fine balance between vasodilator and vasoconstrictor forces. NO is the main vasodilator and endothelin-1(ET-1) the main vasoconstrictor maintaining neonatal intestinal vascular tone (1, 2). Any condition altering this balance has the potential to cause intestinal ischemia and injury. In this review, we will discuss the ontogeny of intestinal vascular regulation, the role of vascular mediators in NEC and factors that influence them. We will also discuss the beneficial effects of breast milk and potential future therapies for NEC that are currently being investigated.

3. Neonatal intestinal vasculature, vascular resistance and changes at birth

In the fetus, the gastrointestinal tract is relatively dormant. Postnatally, it goes through a period of prolific growth and becomes a site of intense metabolic and anabolic activity. There is considerable lengthening of the small intestine from 125 cm at 20 weeks gestation to 275 cm at term and 380 cm at one year (3). Functionally, the intestines assume complete responsibility for assimilation of water and nutrients. The high oxygen demand required for these processes is met by maintaining high blood flow and oxygen delivery to the gut. The superior mesenteric artery (SMA) supplies blood to parts of the intestine derived from midgut (distal duodenum, jejunum, ileum, cecum and appendix, ascending colon, and proximal portion of transverse colon). Since the majority of intestinal blood flow relies on this single vessel, changes in SMA blood flow patterns may have significant physiological effects on the bowel.

Intestinal vascular resistance is high in fetal life and decreases postnatally (4, 5). This could be related to postnatal adaptation as well as the effect of enteral feeds (Table 1). 2-10 d old fed lambs have a higher intestinal blood flow and oxygen uptake as compared to fetal lambs (6). Ultrasound Doppler studies of the SMA in the perinatal period (fetal-30week, 2h, 24h and 72h) in healthy term infants show a similar pattern of increased intestinal perfusion, potentially to meet the increased metabolic demands of the bowel due to the onset of enteral feeding (7). Postnatal intestinal microcirculation in 3 d old swine is characterized by lower resting vascular resistance compared to that of older subjects (8). As the vascular resistance is inversely proportional to the vessel radius to the 4th power, small vasoconstrictive or vasodilatory changes can cause large changes in vascular resistance and blood flow (2, 9).

Table 1. Factors that affect intestinal blood flow
Increase intestinal blood flowDecrease intestinal blood flowReferences
Intrinsic factors
• Nitric oxide• Endothelin-11
• Prostacyclin• Sympathetic stimulation14, 15
• Heparin binding epidermal growth factor HB-EGF26
Extrinsic factors
• Enteral feeding including trophic feeds• Hypoxemia22, 29, 30
• Hypovolemia14
• Patent ductus arteriosus102
• Polycythemia126
• Medications: indomethacin, caffeine103, 105, 127
• Red blood cell transfusions83

3.1. Regulation of intestinal vasculature

The regulation of gastrointestinal blood flow involves both intrinsic and extrinsic mechanisms acting at the tissue level (10). The myogenic component of intrinsic vasoregulation is the innate ability of the vascular smooth muscle to constrict in response to a stimulus. Regulation of tissue oxygenation based on metabolic demand constitutes the metabolic component which is mediated primarily by pre capillary sphincters and factors influencing arteriolar resistance. Reduction in arterial oxygen content decreases blood flow to the intestines and increases flow to brain and heart in fetal lambs through the “diving reflex”(11). The mechanism underlying such regulation at the level of the microcirculation is not well understood. Intestinal circulation in neonatal 3d old swine fails to autoregulate in response to reduced perfusion pressure (12). Reducing the flow rate in isolated perfused gut loops from 3d old swine for a sustained period causes an increase in vascular resistance (13). These findings suggest that reduced oxygen content and reduced perfusion pressure paradoxically further reduce blood flow to the intestines increasing the risk for ischemia.

Extrinsic vasoregulation has a neural and a humoral component. The neural component is mediated by the sympathetic nervous system and the humoral component by circulating vasoactive substances (10). Available experimental evidence suggests that under resting conditions, mucosal perfusion is mainly regulated by the vasodilators (NO and prostacyclin - PGI2), vasoconstrictors (endothelin) and by the sympathetic nervous system (14, 15) (Figure 1). A dynamic balance between vasoconstrictor and vasodilator forces exists in the intestinal vasculature. Vasoconstriction is mediated primarily by ET-1 and vasodilation by NO. In the newborn, this balance heavily favors vasodilation secondary to the copious production of endothelium-derived NO. Endothelial dysfunction occurring as a result of various factors alters this balance thus favoring ET-1-mediated vasoconstriction leading to ischemia and tissue injury (1).

Figure 1. Regulation of the intestinal vasculature. There is a dynamic balance between vasodilators and vasoconstrictors maintaining vascular tone and resistance. Vasodilation is mediated primarily by eNOS derived Nitric Oxide (NO) and prostacyclins. Several factors present in breast milk promote eNOS mediated vasodilation including platelet activating factor acetyl hydrolase (PAF-AH), heparin binding epidermal growth factor (HB-EGF) and tetrahydrobiopterin (BH4). The downstream pathway of vasodilation via NO includes activation of soluble guanyl cyclase (sGC) and cyclic guanosine monophosphate (cGMP). Cyclooxygenase (COX) and prostacyclin synthase (PGIS) are key enzymes involved in production of prostacyclins(PGI2) which activate the cyclic adenosine monophosphate (cAMP) pathway to produce vasodilation. Phosphodiesterase enzymes 3 and 5 (PDE3 and PDE5) degrade cAMP and cGMP respectively. Endothelin 1(ET-1), acting through ET-A receptors and catecholamines acting on the adrenergic receptors act as the primary vasoconstrictors. In addition, reactive oxygen species produced as a result of various metabolic pathways may combine with NO to produce peroxynitrite and cause vasoconstriction. ET-B receptors promote vasodilation through the production of NO, however the vasoconstrictive action through ET-A exceeds the vasodilatory effect through ET-B causing ET-1 to have a net vasoconstrictive effect.

3.2. Vasodilators – NO

NO is produced by the enzyme nitric oxide synthase which has three isoforms- Endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS) and neuronal nitric oxide synthase (nNOS). eNOS and iNOS play a more significant role in maintaining NO in mesenteric vasculature. iNOS is upregulated in certain conditions including inflammation and produces high levels of NO which may contribute to the deleterious effects of NO products such as peroxynitrite. These effects will be discussed later in this review. eNOS is constitutively expressed in the intestinal vasculature and is responsible for the low background levels of NO. This eNOS mediated NO production is thought to contribute to maintenance of vascular tone through the cyclic guanosine monophosphate (cGMP) pathway.

eNOS-derived NO is the most potent vasodilator stimulus present in the newborn intestine(16). NO produced in the endothelium diffuses to adjacent vascular smooth muscle cells, where it binds to the heme moiety of soluble guanylate cyclase (sGC), activating sGC to produce cGMP(1)(Figure 1). Most studies evaluating the role of endothelium derived NO have been performed in sheep and swine. Endogenous NO has been shown to be a significant contributor to the modulation of vascular tone in the GI circulation of mid as well as late-gestation fetal lambs (17, 18) - bib6. Postnatally, this role of nitric oxide is age dependent, being more prominent in 3 d old as compared to 35d old piglets (9). Though abundant eNOS mRNA is present in fetal and postnatal mesenteric arteries (19), eNOS protein peaks at term gestation and remains high in postnatal ovine mesenteric arteries, exhibiting a distinct ontogeny (20).

Several factors may upregulate this mechanism. Flow regulated vasodilation in the intestinal circulation is mediated by eNOS derived NO and is more prominent in the immediate postnatal period (21). Enteral feeds can induce a post prandial hyperemia in splanchnic circulation, the exact etiology of which is not well understood. Doppler ultrasound studies of the mesenteric vessels in preterm infants have shown a post prandial increase in mesenteric flow after the first feed (22). Reber et al noted increased eNOS protein in mesenteric arteries of 1-d-old fed piglets compared with fetal and 1-d-old unfed piglets, suggesting that there may be an upregulation of this enzyme after enteral feeds (19). Other factors that may affect eNOS expression and activity are proinflammatory cytokines, such as tumor necrosis factor (TNF) (23), interleukin-1(IL-1)(24) and toll like receptor 4 (TLR 4) (25). Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of the epidermal growth factor family that has been studied in NEC. HB-EGF also stimulates eNOS protein production and NO release from cells (26).

3.3. Vasoconstrictors- Endothelin and catecholamines

ET-1 is thought to be the primary constrictor stimulus in the intestinal circulation (27) and implicated in intestinal vascular dysfunction and tissue injury. While it exerts its action through receptors A and B (ETRA and ETRB), it has been shown that the force of ETRA-induced vasoconstriction exceeds that of ETRB-generated vasodilation (1). Local, constitutive production of ET-1 helps in establishing basal vascular tone in terminal mesenteric arteries from 1 to 5 day old swine via activation of both ETRA and ETRB receptors (27, 28). ET-1 production can be stimulated by decreased blood flow, hypoxia and various inflammatory cytokines (29, 30).

ET-1 has an age-dependent effect within postnatal intestine, being more prominent in 3 d old as compared to 35 d old swine.(27) Researchers have demonstrated a profound reduction of intestinal perfusion and subsequent tissue damage following intra-arterial infusion of ET-1 (31, 32). Moreover, ET-1 participates in the generation of sustained intestinal ischemia and subsequent tissue damage following a single episode of ischemia-reperfusion (33).

Other vasoconstrictor mediators in newborn intestine include angiotensin (ANG) and catecholamines like norepinephrine (NE). Catecholamines exert their vasoconstrictive effects on circulation via alpha adrenergic receptors. Alpha adrenergic receptor 1A (ADRA1A) appears to be the predominant receptor in mesenteric circulation in rat, dog and humans (34-36). Sustained reduction of blood flow in newborn swine intestine decreases constitutive NO production and subsequently enhances the contractile efficacy of vasoconstrictors ANG II, NE and ET-1 (13). In our studies on ontogeny of ovine mesenteric vasculature, we have shown that mesenteric arterial constriction to NE peaks at 134 d corresponding to late preterm gestation (Figure 2). In addition, ADRA1A mRNA and protein increased significantly at 134d and decreased postnatally, suggesting that mesenteric vasoconstrictive forces predominate in late-preterm gestation (20).

Figure 2. Ontogeny of mesenteric arterial contractility. Distinct ontogenic patterns are noted in mesenteric arterial constriction and relaxation patterns in ovine fetal and postnatal mesenteric arteries. The vasoconstrictive ability of mesenteric arteries in response to ET-1 and Norepinephrine (NE) peaks at 134d (late preterm) gestation and decreases postnatally after enteral feeds. In contrast, the mesenteric arteries of fetal lambs achieve maximal relaxation after birth and enteral feeds. 134d gestation equated to late preterm gestation in humans is characterized by maximal constriction and least relaxation responses. (Adapted from Nair et al, Fetal and postnatal ovine mesenteric vascular reactivity. Pediatr Res. 2016;79(4):575-582).

4. Vascular contribution to etiology of NEC

Abnormalities of intestinal circulation have been observed in NEC. High SMA vascular resistance is noted in preterm babies who later developed NEC (37). Coagulation necrosis, which is characteristic of ischemic injury, was noted in tissue samples of infants with NEC (38). Ischemia and reperfusion injury (I/R) has long been postulated as one of the etiological factors in NEC with preterm neonates being more susceptible to multiple episodes of low flow states, hypotension and hypoxia. Animal models of NEC have utilized hypoxia/reoxygenation to experimentally induce NEC (39). However, risk factors like intrapartum asphyxia, patent ductus arteriosus and umbilical artery catheters are associated with equal frequency in preterm infants with and without NEC (40). This has led to the current presumption that though hypoxia and ischemia are unlikely to be the primary initiating event in preterm infant, the regulation of intestinal circulation, especially the microcirculation, does play a role in NEC pathogenesis.

However, in term infants, a vascular etiology is often identified. Congenital left sided heart disease, gastrointestinal abnormalities, hypoxic ischemic injury as well as polycythemia are various risk factors in term infants that are associated with the development of this process (41). Imbalance in the vasoconstrictor vasodilator balance may contribute to this disease process. Nowicki et al show that while eNOS expression is maintained, eNOS activity and NO production are decreased in mesenteric arterioles isolated from infants with NEC(16). Animal models of NEC have yielded useful information in the role of NO pathway in this condition. NOS blockade decreases intestinal microcirculatory blood flow in a rat model of NEC (42). In human preterm infants with NEC, increased tissue concentration of ET-1 and increased arteriolar vasoconstriction is noted in intestinal samples with evidence of NEC as compared to those from relatively healthy intestine in the same specimen (43). Blockade of ETRA receptors reversed these effects.

4.1. Age at onset of NEC and correlation with ontogeny of mesenteric vasculature

Several studies have noted an inverse relation with gestational age with the most premature infants having the highest risk of developing NEC (44, 45). NEC is rare in term infants, but when it occurs, it presents in the first week of life. NEC is common in extremely premature infants but presents after a few weeks of postnatal life. The median postmenstrual age at NEC presentation is usually around 31-34 weeks (44-46). Some studies have suggested that a unique factor predisposes preterm infants to develop NEC at this postmenstrual age (1). We have previously shown that ovine mesenteric vasoconstriction mediated by endothelin and catecholamines predominates in late-preterm gestation followed by a conversion to vasodilatory influences, mediated by NO, near the time of full-term birth (20)(Figure 2). Distinct ontogenic patterns in vascular reactivity have been noted in chick embryo where maturation of vasodilator mechanisms preceded that of vasoconstrictor mechanisms (47).

5. Non-vasodilatory effects of NO in NEC

While NO derived from vascular endothelium (mainly through eNOS) promotes vasodilation and is protective against NEC, NO derived from other sources – mainly iNOS may play a role in the pathogenesis of NEC. These effects are mediated through intestinal oxygen consumption and/or disruption of the epithelial barrier permitting invasion by an abnormal microbiome.

5.1. Role of NO in intestinal oxygen consumption in NEC

NO has a direct effect on cellular respiration-it reversibly inactivates cytochrome c within the mitochondrial electron transport chain (48). Nowicki et al have shown that iNOS-derived NO suppressed intestinal oxygen consumption in intestine resected for NEC (49). Thus, suppression of intestinal oxygen consumption is yet one more means whereby iNOS-derived NO contributes to the pathogenesis of NEC.

5.2. NO, intestinal barrier function and the microbiome

The pathogenesis of NEC involves disruption of the intestinal epithelial barrier, due to a combination of local and systemic insults (50). NO is thought to play an important role in the intestinal barrier failure seen in NEC. In high concentrations it reacts with superoxide to form its reactive nitrogen derivative peroxynitrite. NO and peroxynitrite may affect gut barrier permeability by inducing enterocyte apoptosis and necrosis(50), or by altering tight junctions or gap junctions that normally play a key role in maintaining epithelial monolayer integrity(51). NO and metabolites may also inhibit the epithelial restitution processes, both enterocyte proliferation and migration (52). While iNOS plays a major role in NO production here, factors that govern iNOS upregulation in the intestine are not well understood. Increased iNOS expression has been noted in intestinal epithelial cells in surgically resected tissue samples of NEC (53). In a rat model of NEC, induced by formula feeding, upregulation of iNOS mRNA, enterocyte apoptosis, and decreased IL-12 production in the intestinal epithelium was noted (54). High levels of NO can lead to increased bacterial translocation by their detrimental effects on the gut barrier (51).

The role of the intestinal microbiome in the pathogenesis of NEC is still being investigated. NEC does not occur in germ free animals (55, 56), however, a definite pathogenic relationship with specific organisms is not seen. It is possible that dysbiosis or altered microbiome plays a role, interacting with an already immature intestine to contribute to NEC. The intestinal microbiome and bacterial colonization begins to get established in the perinatal period. Organisms that colonize the intestines and their components can induce production of NO mediated by iNOS. Infection with Cronobacterium or E. sakazakii induced NEC in a newborn rat model by inducing enterocyte apoptosis (57). Furthermore, this organism in rat intestinal epithelial cells (IEC-6) induced significant production of nitric oxide (NO). This elevated production of NO due to increased expression of iNOS was responsible for apoptosis of IEC-6 cells (58). Better understanding of the role of NO and iNOS induction are necessary for developing iNOS-targeted NEC therapies (52).

6. Role of inflammatory mediators in influencing vasculature in NEC

The final common pathway of NEC involves production of inflammatory mediators induced by ischemia, infectious agents, or mucosal irritants which recruit inflammatory cells and further contribute to tissue injury (59). Some mediators that have been recognized for their role in NEC pathogenesis include TNF, interleukins (IL-1, IL-6, IL-8, IL-10, IL-12, and IL-18) and platelet activating factor (PAF) (60). Preterm infants with NEC show high levels of these cytokines. There is some correlation between levels of cytokines and extent or severity of disease (61, 62) (63).

Some cytokines play a protective role. IL-10 is present in preterm breast milk and a paucity of IL-10 in human milk was found in mothers whose infants developed NEC(64). The mechanism of action is not known. However, intraperitoneal administration of IL-10 has been shown to decrease the severity of intestinal injury and the level of NO synthesized by inhibiting iNOS expression in an IL10 knockout rodent NEC model (65).

Inflammatory mediators also seem to influence vascular tone by interacting with the vasoconstrictors and vasodilators mentioned earlier in this review. PAF, synthesized by many inflammatory cells and bacteria, can cause intestinal necrosis in animals (66). This agent can increase transcription of the vasoconstrictor ET-1 receptor which in turn can further activate PAF (67). Human infants with NEC have increased levels of PAF and decreased expression of PAF acetylhydrolase (PAF-AH), which is the enzyme responsible for degrading PAF (68). Human milk contains PAF-AH but this compound is absent in infant formula. Enteral administration of the recombinant PAF-AH enzyme markedly reduced the incidence of NEC in a rat model of the disease (69).

7. Reactive oxygen species and NEC

Oxidative stress is defined as an imbalance between production of oxidative reactive species and antioxidant defenses. Premature infants, in general, have poor antioxidant defenses since the physiologic increase in antioxidant capacity occurs at the end of gestation (70). Oxidative stress (71) and reactive oxidative species like superoxide have been implicated in NEC pathogenesis. This may involve components of the NO, NADPH oxidase (72) and xanthine oxidase pathway. Certain conditions including tetrahydrobiopterin deficiency can cause uncoupling of eNOS, resulting in a switch from producing NO to superoxide (73). In neonatal rat pups, intestinal ischemia is associated with this NOS dependent uncoupling mechanism causing over-production of reactive oxygen species and impaired vasodilation (74). In addition, stress induces iNOS causing high concentrations of NO in the intestinal microcirculation (74, 75). This NO may react with available superoxide to produce peroxynitrite, another oxidant agent that causes further cellular and tissue damage(76). Magnesium and copper deficiency impair antioxidant defense through decreased synthesis of glutathione and reduced activity of Cu/Zn superoxide dismutase (77). Recently there is some evidence to suggest that maternal magnesium sulfate reduces cytokine IL-6 and TNF-α production in neonates, suggesting potential as therapy in various neonatal inflammatory conditions (78). The role of antioxidants like all-trans-retinoic acid (ATRA) (79) and N-acetylcysteine (NAC)(80) in treating NEC is being investigated in animal models. Enteral glutamine and/or arginine (precursors of NO) supplementation have shown favorable effects on oxidative stress parameters in neonatal rat intestine (81).

8. NO in transfusion associated gut injury

Over the last few years, several studies noted an association between packed red blood cell (PRBC) transfusions and the development of NEC (82-84). “TRAGI” or transfusion associated gut injury, the term proposed by Blau et al (83), was thought to be due to a failure of the postprandial increase in mesenteric blood flow following a transfusion.

Blood products affect arterial reactivity and intestinal motility (85). Beneficial effects of transfusion include hypoxic vasodilation, proposed to be due to the action of NO through S-Nitrosylation of hemoglobin (SNO-Hb). Within red blood cells (RBCs), Hb is S-nitrosylated during the respiratory cycle and thereby conveys NO bioactivity that may be dispensed to regulate local blood flow in the physiologic response known as hypoxic vasodilation. Hb thus both delivers oxygen directly and delivers vasoactivity to potentially optimize tissue perfusion in concert with local metabolic demand. It has been shown recently that storage of blood depletes S-nitrosylated Hb(86), accompanied by reduced ability of RBCs to induce vasodilation. This “storage lesion” appears to account in significant part for the impaired ability of banked RBCs to deliver oxygen. The mechanisms involved include reduced RBC deformability, increased red blood cell adhesion and aggregation, prothrombotic tendency and nitric oxide deficiency(87). Renitrosylation can correct this impairment and thus may offer a means to ameliorate the disruptions in tissue perfusion produced by transfusion(86). PRBC transfusion in enterally fed preterm lambs promotes mesenteric vasoconstriction and impairs vasorelaxation by reducing mesenteric arterial eNOS (88). In addition, recently, investigators have found that PRBC have the potential to release high quantities of the endogenous NOS inhibitors ADMA and LNMMA (89). RBC transfusion can also significantly increase post-transfusion plasma free Hb levels and plasma NO consumption in the recipient (90).

We have evaluated the changes in oxygen extraction and SMA blood flow in preterm lambs (134 d gestation; term ~ 147 d) with anemia induced by partial exchange transfusion (91). Preterm lambs with normal hematocrit had 21.8.7±6.6.5 ml/kg/min of SMA flow and an oxygen extraction ratio (OER) percentage of 9.3.7±1.5. Enteral feed with ewe’s colostrum increased SMA flow and increased oxygen delivery to the intestines (Figure 3). The OER stayed the same. Lambs with anemia had a higher SMA flow at baseline to compensate for lower oxygen content in the blood. Following colostrum feed, SMA blood flow did not further increase but the oxygen demand was met by increased oxygen extraction (Figure 3). Thus, the increased oxygen demand in response to enteral feeding is met by increasing blood flow and/or oxygen extraction. Transfusion of PRBC (7 days old) was followed by an enteral feed. A prior transfusion prevented postprandial increase in intestinal blood flow and oxygen extraction. In the presence of severe anemia and low oxygen delivery to the intestine, we speculate that transfusion followed by feeds increases oxygen demand above oxygen supply leading to ischemia.

Figure 3. Mesenteric arterial flow (A) and oxygen extraction (B) are affected by enteral feeds and transfusions in preterm lambs. After enteral feeds, SMA flow rises significantly in normal preterm lambs (black solid line) without any significant change in oxygen extraction ratio. Transfusion with pRBC (black dashed line) blunts this postprandial rise in flow. Anemic preterm lambs (grey solid line) have a higher baseline SMA flow which does not show any significant change after enteral feeds. Instead, oxygen extraction rises after feed to meet tissue metabolic needs. Transfusion with pRBC in these lambs (grey dashed line) does not change the SMA flow but significantly decreases oxygen extraction as well. (Adapted from Nair et al, Transfusion Decreases Intestinal Oxygen Extraction in Anemic Preterm Lambs After Feeds Pediatric Academic Societies Abstracts, 1705.8. 2014) Figure key: Black solid line- normal preterm lambs, black dashed line- normal preterm lambs transfused with pRBC, grey solid line- anemic preterm lambs, grey dashed line- anemic preterm lambs transfused with pRBC.

More recently, the consensus on the etiopathogenesis of transfusion associated NEC is that the state of chronic anemia contributes significantly to this condition (92). In a large multicenter study in very low birth weight (VLBW) infants, severe anemia, but not RBC transfusion, was associated with an increased risk of NEC (93). Krimmel et al (94) looked at doppler SMA flow velocities and noted that if bolus feedings were preceded by blood transfusions, only anemic neonates weighing <1250 grams failed to develop a postprandial rise in mesenteric artery blood flow velocity. Lower hemoglobin levels may cause gut injury though interactions between hypoxemia, enteric blood flow and feeding. A trial evaluating optimal threshold for transfusion of preterm infants (TOP) is currently recruiting patients and will assess the incidence of NEC in higher and lower hemtocrit threshold groups of preterm infants (Clinical trials no NCT01702805).

9. Influence of common neonatal morbidities in the extremely premature infant on mesenteric vascular regulation and NEC

9.1. Hypotension and dopamine

VLBW infants are prone to several morbidities as a result of their gestational age and immature adaptation abilities. Physiological instability, mechanical ventilation, increased hemodynamic support or extensive neonatal resuscitation and hypotension are reported as additional risk factors for NEC (95). In addition, the use of vasopressors in the first week of life has been shown to be associated with mortality in infants who subsequently developed NEC(96). This likely signifies the extent of their hemodynamic instability and hypotension which contributed to the disease process. One of the most common medications used to manage hypotension is dopamine. However this medication itself may cause significant effects on intestinal vasculature. Dopamine caused smooth muscle contraction in mesenteric arterioles and precapillary sphincters of anesthetized dogs, producing intestinal ischemia and hypoxia (97). While doppler studies in preterm infants have shown that dopamine increased mesenteric blood flow velocity and decreased mesenteric vascular resistance (98), dopamine-induced increases in SMA blood flow have been associated with decreases in oxygen extraction and mucosal blood flow (99, 100).

9.2. Patent ductus arteriosus and indomethacin

A patent ductus arteriosus (PDA) can be a risk factor for NEC (101),(102). Due to the systemic steal phenomenon, there is potentially decreased mesenteric perfusion in a hemodynamically significant PDA, predisposing the infant to intestinal ischemia. Preterm infants with PDA have been reported to have low mesenteric blood flow velocity (103). Indomethacin, ibuprofen and more recently acetaminophen are medications commonly used in the NICU to treat hemodynamically significant PDAs. Indomethacin, a cyclooxygenase (COX) inhibitor, independently reduces intestinal blood flow (104, 105) and has been associated with increased incidence of NEC in VLBW infants (106, 107). However other large studies like the Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP) did not find a significant increase in the risk of NEC with indomethacin as prophylaxis for intraventricular hemorrhage or PDA (108) and it still continues to be used to treat this condition. Ibuprofen does not decrease mesenteric blood flow (105) and may a better pharmacologic choice to treat a PDA without increasing the risk of NEC (109).

10. Therapies in prevention and management of NEC that influence the vasculature

10.1. Breast milk and ingredients

Breast milk is known to be protective in NEC (110, 111). Besides immunological factors like secretory IgA and anti-inflammatory cytokines that are present in breast milk, there are several other compounds such as erythropoietin and oligosaccharides that have been studied in relation to NEC. Breastfeeding also influences the composition of infant’s gut microbiota(112). EGF found in breast milk, has been noted to protect intestinal epithelium against injury (113). Administration of exogenous HB-EGF in rodents protects the intestines from experimental NEC (114). Tetrahydropterin (BH4) present in breast milk is a required cofactor for eNOS coupling and NO generation and has been shown to enhance mesenteric blood flow (115). Exposure to BH4 reduces newborn rat mesenteric arterial vascular tone (116). Higher biopterin concentrations have been observed in human breast milk, when compared with infant formula (116). This may potentially be one of the factors that explain the protective effects of breast milk over formula use in NEC patients.

10.2. Arginine supplementation

NO is synthetized from the conditionally essential amino acid L-arginine by NO synthases (117). Researchers found that continuous intravenous infusion with L-arginine markedly reduced intestinal injury in a neonatal pig model of NEC (118). Premature infants with NEC were noted to have decreased plasma arginine concentrations at the time of diagnosis (119). The role of L-arginine supplementation has been explored in small studies and shows some promise in reducing the incidence of NEC (120, 121). However, larger studies are required to assess its efficacy in preventing NEC in VLBW preterm neonates before widespread use can be recommended.

10.3. Inhaled NO

Inhaled NO exerts beneficial effects on ischemia/reperfusion injury in extra pulmonary organs in animal (122) as well as human studies (123, 124). Administration of inhaled NO has been shown to reduce the size of infarct following stroke in rodent models (125). A similar approach to NEC has been proposed and is being currently investigated in preterm infants (Clinical trials # NCT02851472).

11. Summary and perspective

Similar to the lung, the fetal intestine is a relatively dormant organ whose nutritive function is performed by the placenta. Just as breathing air results in pulmonary vasodilation, enteral feeding reduces intestinal vascular resistance. The intestinal oxygen demand increases with enteral feeding and inability to meet this demand due to stressors such as severe anemia, prematurity and transfusions causing a predominant vasoconstrictor stimulus may lead to disruption of the epithelial barrier. Finally, the complex interaction between intestinal microbiome, epithelial barrier and vasodilators such as NO may play a role in the pathogenesis of NEC. Understanding these interactions may enable us to come up with newer, innovative, preventive and therapeutic strategies against NEC.


    1. C. A. Nankervis, P. J. Giannone and K. M. Reber: The neonatal intestinal vasculature: contributing factors to necrotizing enterocolitis. Semin Perinatol, 32(2), 83-91 (2008)

    2. D. J. Watkins and G. E. Besner: The role of the intestinal microcirculation in necrotizing enterocolitis. Semin Pediatr Surg, 22(2), 83-7 (2013)

    3. L. T. Weaver, S. Austin and T. J. Cole: Small intestinal length: a factor essential for gut adaptation. Gut, 32(11), 1321-3 (1991)

    4. D. I. Edelstone and I. R. Holzman: Fetal intestinal oxygen consumption at various levels of oxygenation. Am J Physiol, 242(1), H50-4 (1982)

    5. I. R. Holzman, B. Tabata and D. I. Edelstone: Effects of varying hematocrit on intestinal oxygen uptake in neonatal lambs. Am J Physiol, 248(4 Pt 1), G432-6 (1985)

    6. K. M. Reber, C. A. Nankervis and P. T. Nowicki: Newborn intestinal circulation. Physiology and pathophysiology. Clin Perinatol, 29(1), 23-39 (2002)

    7. K. Matasova, K. Dokus, P. Zubor, J. Danko and M. Zibolen: Physiological changes in blood flow velocities in the superior mesenteric and coeliac artery in healthy term fetuses and newborns during perinatal period. J Matern Fetal Neonatal Med, 24(6), 827-32 (2011)

    8. K. M. Reber, G. M. Mager, C. E. Miller and P. T. Nowicki: Relationship between flow rate and NO production in postnatal mesenteric arteries. Am J Physiol Gastrointest Liver Physiol, 280(1), G43-50 (2001)

    9. C. A. Nankervis and P. T. Nowicki: Role of nitric oxide in regulation of vascular resistance in postnatal intestine. Am J Physiol, 268(6 Pt 1), G949-58 (1995)

    10. P. R. Kvietys: In: The Gastrointestinal Circulation. San Rafael (CA) (2010)

    11. L. L. Peeters, R. E. Sheldon, M. D. Jones, Jr., E. L. Makowski and G. Meschia: Blood flow to fetal organs as a function of arterial oxygen content. Am J Obstet Gynecol, 135(5), 637-46 (1979)

    12. P. T. Nowicki and C. E. Miller: Autoregulation in the developing postnatal intestinal circulation. Am J Physiol, 254(2 Pt 1), G189-93 (1988)

    13. P. T. Nowicki: Effects of sustained low-flow perfusion on the response to vasoconstrictor agents in postnatal intestine. Am J Physiol, 276(6 Pt 1), G1408-16 (1999)

    14. W. Hasibeder: Gastrointestinal microcirculation: still a mystery? Br J Anaesth, 105(4), 393-6 (2010)

    15. M. B. Hansen, L. S. Dresner and R. B. Wait: Profile of neurohumoral agents on mesenteric and intestinal blood flow in health and disease. Physiol Res, 47(5), 307-27 (1998)

    16. P. T. Nowicki, D. A. Caniano, S. Hammond, P. J. Giannone, G. E. Besner, K. M. Reber and C. A. Nankervis: Endothelial nitric oxide synthase in human intestine resected for necrotizing enterocolitis. J Pediatr, 150(1), 40-5 (2007)

    17. W. Q. Fan, J. J. Smolich, J. Wild, V. Y. Yu and A. M. Walker: Nitric oxide modulates regional blood flow differences in the fetal gastrointestinal tract. Am J Physiol, 271(4 Pt 1), G598-604 (1996)

    18. W. Q. Fan, J. J. Smolich, J. Wild, V. Y. Yu and A. M. Walker: Major vasodilator role for nitric oxide in the gastrointestinal circulation of the mid-gestation fetal lamb. Pediatr Res, 44(3), 344-50 (1998)

    19. K. M. Reber, B. Y. Su, K. R. Clark, D. L. Pohlman, C. E. Miller and P. T. Nowicki: Developmental expression of eNOS in postnatal swine mesenteric artery. Am J Physiol Gastrointest Liver Physiol, 283(6), G1328-35 (2002)

    20. J. Nair, S. F. Gugino, L. C. Nielsen, M. G. Caty and S. Lakshminrusimha: Fetal and postnatal ovine mesenteric vascular reactivity. Pediatr Res, 79(4), 575-82 (2016)

    21. P. T. Nowicki and C. E. Miller: Flow-induced dilation in newborn intestine. Pediatr Res, 38(5), 783-91 (1995)

    22. G. Gladman, D. G. Sims and M. L. Chiswick: Gastrointestinal blood flow velocity after the first feed. Arch Dis Child, 66(1 Spec No), 17-20 (1991)

    23. P. Neumann, N. Gertzberg and A. Johnson: TNF-alpha induces a decrease in eNOS promoter activity. Am J Physiol Lung Cell Mol Physiol, 286(2), L452-9 (2004)

    24. R. Wimalasundera, S. Fexby, L. Regan, S. A. Thom and A. D. Hughes: Effect of tumour necrosis factor-alpha and interleukin 1beta on endothelium-dependent relaxation in rat mesenteric resistance arteries in vitro. Br J Pharmacol, 138(7), 1285-94 (2003)

    25. I. Yazji, C. P. Sodhi, E. K. Lee, M. Good, C. E. Egan, A. Afrazi, M. D. Neal, H. Jia, J. Lin, C. Ma, M. F. Branca, T. Prindle, W. M. Richardson, J. Ozolek, T. R. Billiar, D. G. Binion, M. T. Gladwin and D. J. Hackam: Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOS-NO-nitrite signaling. Proc Natl Acad Sci U S A,110(23), 9451-6 (2013)

    26. V. B. Mehta, Y. Zhou, A. Radulescu and G. E. Besner: HB-EGF stimulates eNOS expression and nitric oxide production and promotes eNOS dependent angiogenesis. Growth Factors, 26(6), 301-15 (2008)

    27. C. A. Nankervis and P. T. Nowicki: Role of endothelin-1 in regulation of the postnatal intestinal circulation. Am J Physiol Gastrointest Liver Physiol, 278(3), G367-75 (2000)

    28. C. A. Nankervis, D. J. Dunaway and P. T. Nowicki: Determinants of terminal mesenteric artery resistance during the first postnatal month. Am J Physiol Gastrointest Liver Physiol, 280(4), G678-86 (2001)

    29. M. J. Kuchan and J. A. Frangos: Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol, 264(1 Pt 2), H150-6 (1993)

    30. M. Woods, J. A. Mitchell, E. G. Wood, S. Barker, N. R. Walcot, G. M. Rees and T. D. Warner: Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol, 55(5), 902-9 (1999)

    31. S. Miura, D. Fukumura, I. Kurose, H. Higuchi, H. Kimura, Y. Tsuzuki, T. Shigematsu, J. Y. Han, M. Tsuchiya and H. Ishii: Roles of ET-1 in endotoxin-induced microcirculatory disturbance in rat small intestine. Am J Physiol, 271(3 Pt 1), G461-9 (1996)

    32. S. Miura, I. Kurose, D. Fukumura, M. Suematsu, E. Sekizuka, H. Tashiro, H. Serizawa, H. Asako and M. Tsuchiya: Ischemic bowel necrosis induced by endothelin-1: an experimental model in rats. Digestion, 48(3), 163-72 (1991)

    33. M. Boros: Microcirculatory dysfunction during intestinal ischemia-reperfusion. Acta Physiol Hung, 90(4), 263-79 (2003)

    34. D. Marti, R. Miquel, K. Ziani, R. Gisbert, M. D. Ivorra, E. Anselmi, L. Moreno, V. Villagrasa, D. Barettino and P. D’Ocon: Correlation between mRNA levels and functional role of alpha1-adrenoceptor subtypes in arteries: evidence of alpha1L as a functional isoform of the alpha1A-adrenoceptor. Am J Physiol Heart Circ Physiol, 289(5), H1923-32 (2005)

    35. S. G. Martinez-Salas, J. M. Campos-Peralta, J. Pares-Hipolito, I. A. Gallardo-Ortiz, M. Ibarra and R. Villalobos-Molina: Alpha1A-adrenoceptors predominate in the control of blood pressure in mouse mesenteric vascular bed. Auton Autacoid Pharmacol, 27(3), 137-42 (2007)

    36. X. L. Rudner, D. E. Berkowitz, J. V. Booth, B. L. Funk, K. L. Cozart, E. B. D’Amico, H. El-Moalem, S. O. Page, C. D. Richardson, B. Winters, L. Marucci and D. A. Schwinn: Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation, 100(23), 2336-43 (1999)

    37. E. M. Murdoch, A. K. Sinha, S. T. Shanmugalingam, G. C. Smith and S. T. Kempley: Doppler flow velocimetry in the superior mesenteric artery on the first day of life in preterm infants and the risk of neonatal necrotizing enterocolitis. Pediatrics,118(5), 1999-2003 (2006)

    38. W. A. Ballance, B. B. Dahms, N. Shenker and R. M. Kliegman: Pathology of neonatal necrotizing enterocolitis: a ten-year experience. J Pediatr,117(1 Pt 2), S6-13 (1990)

    39. A. Kazez, N. Kucukaydin, M. Kucukaydin, O. Kontas, H. Okur and P. Dogan: A model of hypoxia-induced necrotizing enterocolitis: the role of distension. J Pediatr Surg, 32(10), 1466-9 (1997)

    40. B. J. Stoll, W. P. Kanto, Jr., R. I. Glass, A. J. Nahmias and A. W. Brann, Jr.: Epidemiology of necrotizing enterocolitis: a case control study. J Pediatr, 96(3 Pt 1), 447-51 (1980)

    41. R. D. Christensen, D. K. Lambert, V. L. Baer and P. V. Gordon: Necrotizing enterocolitis in term infants. Clin Perinatol, 40(1), 69-78 (2013)

    42. C. D. Downard, P. J. Matheson, J. A. Shepherd, A. C. Maki and R. N. Garrison: Direct peritoneal resuscitation augments ileal blood flow in necrotizing enterocolitis via a novel mechanism. J Pediatr Surg, 47(6),1128-34 (2012)

    43. P. T. Nowicki, D. J. Dunaway, C. A. Nankervis, P. J. Giannone, K. M. Reber, S. B. Hammond, G. E. Besner and D. A. Caniano: Endothelin-1 in human intestine resected for necrotizing enterocolitis. J Pediatr, 146(6), 805-10 (2005)

    44. R. Gonzalez-Rivera, R. C. Culverhouse, A. Hamvas, P. I. Tarr and B. B. Warner: The age of necrotizing enterocolitis onset: an application of Sartwell’s incubation period model. J Perinatol, 31(8), 519-23 (2011)

    45. A. R. Llanos, M. E. Moss, M. C. Pinzon, T. Dye, R. A. Sinkin and J. W. Kendig: Epidemiology of neonatal necrotising enterocolitis: a population-based study. Paediatr Perinat Epidemiol, 16(4), 342-9 (2002)

    46. J. Neu: Neonatal necrotizing enterocolitis: an update. Acta Paediatr Suppl, 94(449), 100-5 (2005)

    47. R. M. Moonen and E. Villamor: Developmental changes in mesenteric artery reactivity in embryonic and newly hatched chicks. J Comp Physiol B, 181(8), 1063-73 (2011)

    48. M. W. Cleeter, J. M. Cooper, V. M. Darley-Usmar, S. Moncada and A. H. Schapira: Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett, 345(1), 50-4 (1994)

    49. P. T. Nowicki, K. M. Reber, P. J. Giannone, C. A. Nankervis, S. Hammond, G. E. Besner and D. A. Caniano: Intestinal O2 consumption in necrotizing enterocolitis: role of nitric oxide. Pediatr Res, 59(4 Pt 1), 500-5 (2006)

    50. D. J. Hackam, J. S. Upperman, A. Grishin and H. R. Ford: Disordered enterocyte signaling and intestinal barrier dysfunction in the pathogenesis of necrotizing enterocolitis. Semin Pediatr Surg, 14(1), 49-57 (2005)

    51. L. L. Wu, H. D. Chiu, W. H. Peng, B. R. Lin, K. S. Lu, Y. Z. Lu and L. C. Yu: Epithelial inducible nitric oxide synthase causes bacterial translocation by impairment of enterocytic tight junctions via intracellular signals of Rho-associated kinase and protein kinase C zeta. Crit Care Med, 39(9), 2087-98 (2011)

    52. A. Grishin, J. Bowling, B. Bell, J. Wang and H. R. Ford: Roles of nitric oxide and intestinal microbiota in the pathogenesis of necrotizing enterocolitis. J Pediatr Surg, 51(1), 13-7 (2016)

    53. H. Ford, S. Watkins, K. Reblock and M. Rowe: The role of inflammatory cytokines and nitric oxide in the pathogenesis of necrotizing enterocolitis. J Pediatr Surg, 32(2), 275-82 (1997)

    54. E. P. Nadler, E. Dickinson, A. Knisely, X. R. Zhang, P. Boyle, D. Beer-Stolz, S. C. Watkins and H. R. Ford: Expression of inducible nitric oxide synthase and interleukin-12 in experimental necrotizing enterocolitis. J Surg Res, 92(1), 71-7 (2000)

    55. C. A. Musemeche, A. M. Kosloske, S. A. Bartow and E. T. Umland: Comparative effects of ischemia, bacteria, and substrate on the pathogenesis of intestinal necrosis. J Pediatr Surg, 21(6), 536-8 (1986)

    56. T. Jilling, D. Simon, J. Lu, F. J. Meng, D. Li, R. Schy, R. B. Thomson, A. Soliman, M. Arditi and M. S. Caplan: The roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol, 177(5), 3273-82 (2006)

    57. C. J. Hunter, V. K. Singamsetty, N. K. Chokshi, P. Boyle, V. Camerini, A. V. Grishin, J. S. Upperman, H. R. Ford and N. V. Prasadarao: Enterobacter sakazakii enhances epithelial cell injury by inducing apoptosis in a rat model of necrotizing enterocolitis. J Infect Dis, 198(4), 586-93 (2008)

    58. C. J. Hunter, M. Williams, M. Petrosyan, Y. Guner, R. Mittal, D. Mock, J. S. Upperman, H. R. Ford and N. V. Prasadarao: Lactobacillus bulgaricus prevents intestinal epithelial cell injury caused by Enterobacter sakazakii-induced nitric oxide both in vitro and in the newborn rat model of necrotizing enterocolitis. Infect Immun, 77(3), 1031-43 (2009)

    59. M. S. Caplan and W. Hsueh: Necrotizing enterocolitis: role of platelet activating factor, endotoxin, and tumor necrosis factor. J Pediatr,117(1 Pt 2), S47-51 (1990)

    60. C. J. Hunter and I. G. De Plaen: Inflammatory signaling in NEC: Role of NF-kappaB, cytokines and other inflammatory mediators. Pathophysiology, 21(1), 55-65 (2014)

    61. J. A. Morecroft, L. Spitz, P. A. Hamilton and S. J. Holmes: Plasma cytokine levels in necrotizing enterocolitis. Acta Paediatr Suppl, 396, 18-20 (1994)

    62. M. C. Harris, A. T. Costarino, Jr., J. S. Sullivan, S. Dulkerian, L. McCawley, L. Corcoran, S. Butler and L. Kilpatrick: Cytokine elevations in critically ill infants with sepsis and necrotizing enterocolitis. J Pediatr, 124(1), 105-11 (1994)

    63. T. Benkoe, C. Reck, A. Gleiss, S. Kettner, A. Repa, E. Horcher and W. Rebhandl: Interleukin 8 correlates with intestinal involvement in surgically treated infants with necrotizing enterocolitis. J Pediatr Surg, 47(8), 1548-54 (2012)

    64. C. C. Fituch, K. H. Palkowetz, A. S. Goldman and R. J. Schanler: Concentrations of IL-10 in preterm human milk and in milk from mothers of infants with necrotizing enterocolitis. Acta Paediatr, 93(11), 1496-500 (2004)

    65. K. M. Kling, L. Kirby, K. Y. Kwan, F. Kim and D. W. McFadden: Interleukin-10 inhibits inducible nitric oxide synthase in an animal model of necrotizing enterocolitis. Int J Surg Investig, 1(4), 337-42 (1999)

    66. W. Hsueh, F. Gonzalez-Crussi and J. L. Arroyave: Platelet-activating factor-induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis. Am J Pathol, 122(2), 231-9 (1986)

    67. S. B. Mustafa, C. R. Gandhi, S. A. Harvey and M. S. Olson: Endothelin stimulates platelet-activating factor synthesis by cultured rat Kupffer cells. Hepatology, 21(2), 545-53 (1995)

    68. M. S. Caplan, X. M. Sun, W. Hseuh and J. R. Hageman: Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr,116(6), 960-4 (1990)

    69. M. S. Caplan, M. Lickerman, L. Adler, G. N. Dietsch and A. Yu: The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis. Pediatr Res, 42(6), 779-83 (1997)

    70. C. Yzydorczyk, D. Mitanchez, C. Buffat, I. Ligi, I. Grandvuillemin, F. Boubred and U. Simeoni: (Oxidative stress after preterm birth: origins, biomarkers, and possible therapeutic approaches). Arch Pediatr, 22(10), 1047-55 (2015)

    71. C. Aydemir, D. Dilli, N. Uras, H. O. Ulu, S. S. Oguz, O. Erdeve and U. Dilmen: Total oxidant status and oxidative stress are increased in infants with necrotizing enterocolitis. J Pediatr Surg, 46(11), 2096-100 (2011)

    72. S. R. Welak, R. M. Rentea, R. J. Teng, N. Heinzerling, B. Biesterveld, J. L. Liedel, K. A. Pritchard, Jr., K. M. Fredrich and D. M. Gourlay: Intestinal NADPH oxidase 2 activity increases in a neonatal rat model of necrotizing enterocolitis. PLoS One, 9(12), e115317 (2014)

    73. M. L. Pall: Nitric oxide synthase partial uncoupling as a key switching mechanism for the NO/ONOO- cycle. Med Hypotheses, 69(4), 821-5 (2007)

    74. J. S. Whitehouse, H. Xu, Y. Shi, L. Noll, S. Kaul, D. W. Jones, K. A. Pritchard, Jr., K. T. Oldham and D. M. Gourlay: Mesenteric nitric oxide and superoxide production in experimental necrotizing enterocolitis. J Surg Res, 161(1), 1-8 (2010)

    75. P. J. Andrew and B. Mayer: Enzymatic function of nitric oxide synthases. Cardiovasc Res, 43(3), 521-31 (1999)

    76. J. S. Beckman and W. H. Koppenol: Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol, 271(5 Pt 1), C1424-37 (1996)

    77. J. L. Caddell: A review of evidence for a role of magnesium and possibly copper deficiency in necrotizing enterocolitis. Magnes Res, 9(1), 55-66 (1996)

    78. J. Sugimoto, A. M. Romani, A. M. Valentin-Torres, A. A. Luciano, C. M. Ramirez Kitchen, N. Funderburg, S. Mesiano and H. B. Bernstein: Magnesium decreases inflammatory cytokine production: a novel innate immunomodulatory mechanism. J Immunol, 188(12), 6338-46 (2012)

    79. R. Ozdemir, S. Yurttutan, F. N. Sari, M. Y. Oncel, O. Erdeve, H. G. Unverdi, B. Uysal and U. Dilmen: All-trans-retinoic acid attenuates intestinal injury in a neonatal rat model of necrotizing enterocolitis. Neonatology, 104(1), 22-7 (2013)

    80. R. Ozdemir, S. Yurttutan, F. N. Sari, B. Uysal, H. G. Unverdi, F. E. Canpolat, O. Erdeve and U. Dilmen: Antioxidant effects of N-acetylcysteine in a neonatal rat model of necrotizing enterocolitis. J Pediatr Surg, 47(9), 1652-7 (2012)

    81. M. Kul, S. Vurucu, E. Demirkaya, T. Tunc, S. Aydinoz, C. Meral, V. Kesik and F. Alpay: Enteral glutamine and/or arginine supplementation have favorable effects on oxidative stress parameters in neonatal rat intestine. J Pediatr Gastroenterol Nutr, 49(1), 85-9 (2009)

    82. G. A. McGrady, P. J. Rettig, G. R. Istre, J. M. Jason, R. C. Holman and B. L. Evatt: An outbreak of necrotizing enterocolitis. Association with transfusions of packed red blood cells. Am J Epidemiol, 126(6),1165-72 (1987)

    83. J. Blau, J. M. Calo, D. Dozor, M. Sutton, G. Alpan and E. F. La Gamma: Transfusion-related acute gut injury: necrotizing enterocolitis in very low birth weight neonates after packed red blood cell transfusion. J Pediatr, 158(3), 403-9 (2011)

    84. R. D. Christensen, D. K. Lambert, E. Henry, S. E. Wiedmeier, G. L. Snow, V. L. Baer, E. Gerday, S. Ilstrup and T. J. Pysher: Is “transfusion-associated necrotizing enterocolitis” an authentic pathogenic entity? Transfusion, 50(5),1106-12 (2010)

    85. G. N. Stewart and T. F. Zucker: A Comparison of the Action of Plasma and Serum on Certain Objects Used in Biological Tests for Epinephrine. J Exp Med, 17(2), 152-73 (1913)

    86. J. D. Reynolds, D. T. Hess and J. S. Stamler: The transfusion problem: role of aberrant S-nitrosylation. Transfusion, 51(4), 852-8 (2011)

    87. M. T. Gladwin and D. B. Kim-Shapiro: Storage lesion in banked blood due to hemolysis-dependent disruption of nitric oxide homeostasis. Curr Opin Hematol, 16(6), 515-23 (2009)

    88. J. Nair, S. F. Gugino, L. C. Nielsen, C. Allen, J. A. Russell, B. Mathew, D. D. Swartz and S. Lakshminrusimha: Packed red cell transfusions alter mesenteric arterial reactivity and nitric oxide pathway in preterm lambs. Pediatr Res, 74(6), 652-7 (2013)

    89. C. F. Zwemer, R. D. Davenport, J. Gomez-Espina, E. Blanco-Gonzalez, S. E. Whitesall and L. G. D’Alecy: Packed red blood cells are an abundant and proximate potential source of nitric oxide synthase inhibition. PLoS One, 10(3), e0119991 (2015)

    90. I. C. Vermeulen Windsant, N. C. de Wit, J. T. Sertorio, E. A. Beckers, J. E. Tanus-Santos, M. J. Jacobs and W. A. Buurman: Blood transfusions increase circulating plasma free hemoglobin levels and plasma nitric oxide consumption: a prospective observational pilot study. Crit Care, 16(3), R95 (2012)

    91. J. Nair, S. F. Gugino, C. Koenigsknecht, D. D. Swartz and S. Lakshminrusimha: Transfusion Decreases Intestinal Oxygen Extraction in Anemic Preterm Lambs After Feeds Pediatric Academic Societies Abstracts, 1705.8. (2014)

    92. R. Singh, B. L. Shah and I. D. Frantz, 3rd: Necrotizing enterocolitis and the role of anemia of prematurity. Semin Perinatol, 36(4), 277-82 (2012)

    93. R. M. Patel, A. Knezevic, N. Shenvi, M. Hinkes, S. Keene, J. D. Roback, K. A. Easley and C. D. Josephson: Association of Red Blood Cell Transfusion, Anemia, and Necrotizing Enterocolitis in Very Low-Birth-Weight Infants. JAMA, 315(9), 889-97 (2016)

    94. G. A. Krimmel, R. Baker and T. D. Yanowitz: Blood transfusion alters the superior mesenteric artery blood flow velocity response to feeding in premature infants. Am J Perinatol, 26(2), 99-105 (2009)

    95. K. E. Gregory: Clinical predictors of necrotizing enterocolitis in premature infants. Nurs Res, 57(4), 260-70 (2008)

    96. R. H. Clark, P. Gordon, W. M. Walker, M. Laughon, P. B. Smith and A. R. Spitzer: Characteristics of patients who die of necrotizing enterocolitis. J Perinatol, 32(3), 199-204 (2012)

    97. W. Pawlik, D. Mailman, L. L. Shanbour and E. D. Jacobson: Dopamine effects on the intestinal circulation. Am Heart J, 91(3), 325-31 (1976)

    98. R. Hentschel, D. Hensel, T. Brune, H. Rabe and G. Jorch: Impact on blood pressure and intestinal perfusion of dobutamine or dopamine in hypotensive preterm infants. Biol Neonate, 68(5), 318-24 (1995)

    99. G. D. Giraud and K. L. MacCannell: Decreased nutrient blood flow during dopamine- and epinephrine-induced intestinal vasodilation. J Pharmacol Exp Ther, 230(1), 214-20 (1984)

    100. S. Gelman and P. S. Mushlin: Catecholamine-induced changes in the splanchnic circulation affecting systemic hemodynamics. Anesthesiology, 100(2), 434-9 (2004)

    101. S. Dollberg, A. Lusky and B. Reichman: Patent ductus arteriosus, indomethacin and necrotizing enterocolitis in very low birth weight infants: a population-based study. J Pediatr Gastroenterol Nutr, 40(2), 184-8 (2005)

    102. E. Bertino, F. Giuliani, G. Prandi, A. Coscia, C. Martano and C. Fabris: Necrotizing enterocolitis: risk factor analysis and role of gastric residuals in very low birth weight infants. J Pediatr Gastroenterol Nutr, 48(4), 437-42 (2009)

    103. S. Shimada, T. Kasai, A. Hoshi, A. Murata and S. Chida: Cardiocirculatory effects of patent ductus arteriosus in extremely low-birth-weight infants with respiratory distress syndrome. Pediatr Int, 45(3), 255-62 (2003)

    104. S. Shimada, T. Kasai, M. Konishi and T. Fujiwara: Effects of patent ductus arteriosus on left ventricular output and organ blood flows in preterm infants with respiratory distress syndrome treated with surfactant. J Pediatr, 125(2), 270-7 (1994)

    105. M. Pezzati, V. Vangi, R. Biagiotti, G. Bertini, D. Cianciulli and F. F. Rubaltelli: Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr, 135(6), 733-8 (1999)

    106. A. M. Fujii, E. Brown, M. Mirochnick, S. O’Brien and G. Kaufman: Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol, 22(7), 535-40 (2002)

    107. J. L. Grosfeld, M. Chaet, F. Molinari, W. Engle, S. A. Engum, K. W. West, F. J. Rescorla and L. R. Scherer, 3rd: Increased risk of necrotizing enterocolitis in premature infants with patent ductus arteriosus treated with indomethacin. Ann Surg, 224(3), 350-5; discussion 355-7 (1996)

    108. B. Schmidt, P. Davis, D. Moddemann, A. Ohlsson, R. S. Roberts, S. Saigal, A. Solimano, M. Vincer, L. L. Wright and I. Trial of Indomethacin Prophylaxis in Preterms: Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med, 344(26), 1966-72 (2001)

    109. A. Ohlsson, R. Walia and S. S. Shah: Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev(2), CD003481 (2015)

    110. A. Lucas and T. J. Cole: Breast milk and neonatal necrotising enterocolitis. Lancet, 336(8730), 1519-23 (1990)

    111. S. Sullivan, R. J. Schanler, J. H. Kim, A. L. Patel, R. Trawoger, U. Kiechl-Kohlendorfer, G. M. Chan, C. L. Blanco, S. Abrams, C. M. Cotten, N. Laroia, R. A. Ehrenkranz, G. Dudell, E. A. Cristofalo, P. Meier, M. L. Lee, D. J. Rechtman and A. Lucas: An exclusively human milk-based diet is associated with a lower rate of necrotizing enterocolitis than a diet of human milk and bovine milk-based products. J Pediatr, 156(4), 562-7 e1 (2010)

    112. S. E. Balmer and B. A. Wharton: Diet and faecal flora in the newborn: breast milk and infant formula. Arch Dis Child, 64(12), 1672-7 (1989)

    113. C. L. Wagner, S. N. Taylor and D. Johnson: Host factors in amniotic fluid and breast milk that contribute to gut maturation. Clin Rev Allergy Immunol, 34(2), 191-204 (2008)

    114. J. Feng, O. N. El-Assal and G. E. Besner: Heparin-binding epidermal growth factor-like growth factor decreases the incidence of necrotizing enterocolitis in neonatal rats. J Pediatr Surg, 41(1), 144-9; discussion 144-9 (2006)

    115. Y. M. Yang, A. Huang, G. Kaley and D. Sun: eNOS uncoupling and endothelial dysfunction in aged vessels. Am J Physiol Heart Circ Physiol, 297(5), H1829-36 (2009)

    116. A. Weinmann, M. Post, J. Pan, M. Rafi, D. L. O’Connor, S. Unger, P. Pencharz and J. Belik: Tetrahydrobiopterin is present in high quantity in human milk and has a vasorelaxing effect on newborn rat mesenteric arteries. Pediatr Res, 69(4), 325-9 (2011)

    117. S. Moncada and A. Higgs: The L-arginine-nitric oxide pathway. N Engl J Med, 329(27), 2002-12 (1993)

    118. M. Di Lorenzo, J. Bass and A. Krantis: Use of L-arginine in the treatment of experimental necrotizing enterocolitis. J Pediatr Surg, 30(2), 235-40; discussion 240-1 (1995)

    119. S. A. Zamora, H. J. Amin, D. D. McMillan, P. Kubes, G. H. Fick, J. D. Butzner, H. G. Parsons and R. B. Scott: Plasma L-arginine concentrations in premature infants with necrotizing enterocolitis. J Pediatr, 131(2), 226-32 (1997)

    120. E. Polycarpou, S. Zachaki, M. Tsolia, V. Papaevangelou, N. Polycarpou, D. D. Briana, S. Gavrili, C. Kostalos and D. Kafetzis: Enteral L-arginine supplementation for prevention of necrotizing enterocolitis in very low birth weight neonates: a double-blind randomized pilot study of efficacy and safety. JPEN J Parenter Enteral Nutr, 37(5), 617-22 (2013)

    121. H. J. Amin, S. A. Zamora, D. D. McMillan, G. H. Fick, J. D. Butzner, H. G. Parsons and R. B. Scott: Arginine supplementation prevents necrotizing enterocolitis in the premature infant. J Pediatr, 140(4), 425-31 (2002)

    122. B. Guery, R. Neviere, N. Viget, C. Foucher, P. Fialdes, F. Wattel and G. Beaucaire: Inhaled NO preadministration modulates local and remote ischemia-reperfusion organ injury in a rat model. J Appl Physiol (1985), 87(1), 47-53 (1999)

    123. J. D. Lang, Jr., X. Teng, P. Chumley, J. H. Crawford, T. S. Isbell, B. K. Chacko, Y. Liu, N. Jhala, D. R. Crowe, A. B. Smith, R. C. Cross, L. Frenette, E. E. Kelley, D. W. Wilhite, C. R. Hall, G. P. Page, M. B. Fallon, J. S. Bynon, D. E. Eckhoff and R. P. PaTel: Inhaled NO accelerates restoration of liver function in adults following orthotopic liver transplantation. J Clin Invest,117(9), 2583-91 (2007)

    124. M. Mathru, R. Huda, D. R. Solanki, S. Hays and J. D. Lang: Inhaled nitric oxide attenuates reperfusion inflammatory responses in humans. Anesthesiology, 106(2), 275-82 (2007)

    125. X. Liu, Y. Huang, P. Pokreisz, P. Vermeersch, G. Marsboom, M. Swinnen, E. Verbeken, J. Santos, M. Pellens, H. Gillijns, F. Van de Werf, K. D. Bloch and S. Janssens: Nitric oxide inhalation improves microvascular flow and decreases infarction size after myocardial ischemia and reperfusion. J Am Coll Cardiol, 50(8), 808-17 (2007)

Share and Cite
Jayasree Nair, Satyan Lakshminrusimha. Role of NO and other vascular mediators in the etiopathogenesis of necrotizing enterocolitis. Frontiers in Bioscience-Scholar. 2019. 11(1); 9-28.